Another promising target with regard to prostate cancer [12] is the gastrin-releasing peptide receptor (GRPR), which was shown to be overexpressed not only in prostate but also in breast cancer [13], as well as gastrointestinal stromal tumors [14], amongst others. This evidence concerns the gene GRPR and breast carcinoma.